INO-CD22: A Multi-Center, Real-Life Study on Inotuzumab-Ozogamicin Safety and Effectiveness in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia

MLA

Papayannidis, Cristina, et al. “INO-CD22: A Multi-Center, Real-Life Study on Inotuzumab-Ozogamicin Safety and Effectiveness in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia.” Blood, vol. 138, no. Supplement 1, Nov. 2021, p. 4391. EBSCOhost, https://doi.org/10.1182/blood-2021-149157.

APA

Papayannidis, C., Zappasodi, P., Fracchiolla, N. S., Di Raimondo, F., Mattei, D. G., Lanza, F., Mauro, E., Del Principe, M. I., Borlenghi, E., Fumagalli, M., Todisco, E., Sica, S., Di Renzo, N., De Fabritiis, P., Corradini, P., Vallisa, D., Petruzziello, F., Luppi, M., Pane, F., … Martinelli, G. (2021). INO-CD22: A Multi-Center, Real-Life Study on Inotuzumab-Ozogamicin Safety and Effectiveness in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia. Blood, 138(Supplement 1), 4391. https://doi.org/10.1182/blood-2021-149157

Chicago

Papayannidis, Cristina, Patrizia Zappasodi, Nicola S Fracchiolla, Francesco Di Raimondo, Daniele Giovanni Mattei, Francesco Lanza, Endri Mauro, et al. 2021. “INO-CD22: A Multi-Center, Real-Life Study on Inotuzumab-Ozogamicin Safety and Effectiveness in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia.” Blood 138 (Supplement 1): 4391. doi:10.1182/blood-2021-149157.